Table 2.
Research gaps and opportunities
Area | Maternal Topics | Neonatal Topics |
---|---|---|
Prevention of infection | Yes | Yes |
Prediction of infection | Yes Colonization versus infection |
Yes |
Scoring system for probability of sepsis; infection prediction models to guide clinical management | Yes, placental histology, microbiome | Yes – need to define by GA, microbiome |
Isolated fever in labor | Management – antipyretics, NSAIDs, antimicrobial agents | Management evaluation and antimicrobial agents |
Biomarkers | Prediction, Consensus for design of biomarker validation studies and/or reporting of accuracy | Prediction, guidance for management, consensus for design of biomarker validation studies or reporting of accuracy |
Outcomes | In hospital; subsequent reproductive outcomes | In-hospital, morbidities; longer term outcomes including neurodevelopment |
Antimicrobial agents | Timing, duration, selection of antimicrobial agents used | Timing, duration, selection of antimicrobial agents used |
Post-partum events | Fever, clinical course and its relationship to newborn’s care and management | |
“Epidural fever” investigation | Management and treatment | Management and treatment |
Maternal Fever | Timing, duration, height and impact on clinical care and course | Timing, duration, height and impact on clinical care and course |
Duration of antimicrobial therapy | Timing and selection of antimicrobial agents | Term infant- well appearing-Term infant –symptomatic Term infant – resolved minor symptoms Preterm infant |
Link studies – mother and baby cohorts | Impact of infection on neurodevelopment impairment or CP | |
Observation versus treatment | Low risk cohorts | |
Corticosteroids | Effects –short and long term | Effects prenatal and post-natal |
Microbiome – maternal-fetal microbiome ecosystem | Perturbations, influence of GI flora on GU flora | Symbiosis versus pathology |